Published in J Cell Biochem on January 01, 2004
Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst (2009) 2.53
Protein partners of deubiquitinating enzymes. Biochem J (2008) 2.15
AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol (2010) 2.11
Hormonal control of androgen receptor function through SIRT1. Mol Cell Biol (2006) 1.91
MondoA-Mlx heterodimers are candidate sensors of cellular energy status: mitochondrial localization and direct regulation of glycolysis. Mol Cell Biol (2006) 1.48
Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. Prog Lipid Res (2013) 1.46
Deubiquitinating enzymes as novel anticancer targets. Future Oncol (2007) 1.43
Defining aggressive prostate cancer using a 12-gene model. Neoplasia (2006) 1.39
Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J Cell Mol Med (2013) 1.38
Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells. Mol Cancer Res (2011) 1.37
Inactivation of AMPK alters gene expression and promotes growth of prostate cancer cells. Oncogene (2009) 1.34
Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer. Lab Invest (2008) 1.30
Epigenetic responses to environmental change and their evolutionary implications. Philos Trans R Soc Lond B Biol Sci (2009) 1.14
The functional significance of nuclear receptor acetylation. Steroids (2007) 1.04
Androgen receptor survival signaling is blocked by anti-beta2-microglobulin monoclonal antibody via a MAPK/lipogenic pathway in human prostate cancer cells. J Biol Chem (2010) 1.04
Expression analysis of imbalanced genes in prostate carcinoma using tissue microarrays. Br J Cancer (2006) 1.03
MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cells. PLoS One (2013) 1.03
Blood and tissue biomarkers in prostate cancer: state of the art. Urol Clin North Am (2010) 1.02
A mutant of hepatitis B virus X protein (HBxDelta127) promotes cell growth through a positive feedback loop involving 5-lipoxygenase and fatty acid synthase. Neoplasia (2010) 1.01
The role of glucose metabolism and glucose-associated signalling in cancer. Perspect Medicin Chem (2008) 0.99
Evidence of aberrant lipid metabolism in hepatitis C and hepatocellular carcinoma. HPB (Oxford) (2010) 0.98
Ubiquitin-specific cysteine protease 2a (USP2a) regulates the stability of Aurora-A. J Biol Chem (2011) 0.97
Oxidized LDL receptor 1 (OLR1) as a possible link between obesity, dyslipidemia and cancer. PLoS One (2011) 0.97
AMPK: a cellular metabolic and redox sensor. A minireview. Front Biosci (Landmark Ed) (2014) 0.97
Anticancer Properties of PPARalpha-Effects on Cellular Metabolism and Inflammation. PPAR Res (2008) 0.96
Lipid metabolism in prostate cancer. Am J Clin Exp Urol (2014) 0.96
Androgens promote prostate cancer cell growth through induction of autophagy. Mol Endocrinol (2012) 0.95
Establishing a relationship between prolactin and altered fatty acid β-oxidation via carnitine palmitoyl transferase 1 in breast cancer cells. BMC Cancer (2011) 0.95
Roles of StearoylCoA Desaturase-1 in the Regulation of Cancer Cell Growth, Survival and Tumorigenesis. Cancers (Basel) (2011) 0.94
Acetylation in nuclear receptor signaling and the role of sirtuins. Mol Endocrinol (2007) 0.91
Natural compounds as regulators of the cancer cell metabolism. Int J Cell Biol (2013) 0.91
Early growth response 1 and fatty acid synthase expression is altered in tumor adjacent prostate tissue and indicates field cancerization. Prostate (2011) 0.89
Guanylyl cyclase C in colorectal cancer: susceptibility gene and potential therapeutic target. Future Oncol (2009) 0.87
Autophagy regulates lipolysis and cell survival through lipid droplet degradation in androgen-sensitive prostate cancer cells. Prostate (2012) 0.87
Blockade of fatty acid synthase triggers significant apoptosis in mantle cell lymphoma. PLoS One (2012) 0.86
Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies. Mol Aspects Med (2013) 0.85
Molecular pathways involved in prostate carcinogenesis: insights from public microarray datasets. PLoS One (2012) 0.85
Retracted Fatty acid synthase is a novel therapeutic target in multiple myeloma. Br J Haematol (2008) 0.85
Metabolic regulation of invadopodia and invasion by acetyl-CoA carboxylase 1 and de novo lipogenesis. PLoS One (2012) 0.84
Deletion hotspots in AMACR promoter CpG island are cis-regulatory elements controlling the gene expression in the colon. PLoS Genet (2009) 0.84
Differential expression of fatty acid synthase (FAS) and ErbB2 in nonmalignant and malignant oral keratinocytes. Virchows Arch (2008) 0.83
Dual activation of pathways regulated by steroid receptors and peptide growth factors in primary prostate cancer revealed by Factor Analysis of microarray data. BMC Genomics (2005) 0.83
PPARs: Interference with Warburg' Effect and Clinical Anticancer Trials. PPAR Res (2012) 0.83
PET Imaging of Prostate Cancer Using C-Acetate. PET Clin (2009) 0.83
Measure transcript integrity using RNA-seq data. BMC Bioinformatics (2016) 0.83
Innovation in metabolomics to improve personalized healthcare. Ann N Y Acad Sci (2015) 0.82
The pathogenesis of prostate cancer: from molecular to metabolic alterations. Diagn Histopathol (Oxf) (2008) 0.81
Fatty acid synthase inhibitors induce apoptosis in non-tumorigenic melan-a cells associated with inhibition of mitochondrial respiration. PLoS One (2014) 0.81
Examining the relationship between obesity and prostate cancer. Rev Urol (2004) 0.81
Small Molecule Inhibition of the Ubiquitin-specific Protease USP2 Accelerates cyclin D1 Degradation and Leads to Cell Cycle Arrest in Colorectal Cancer and Mantle Cell Lymphoma Models. J Biol Chem (2016) 0.78
Regulation of invadopodia by the tumor microenvironment. Cell Adh Migr (2014) 0.78
Combination of body mass index and oxidized low density lipoprotein receptor 1 in prognosis prediction of patients with squamous non-small cell lung cancer. Oncotarget (2015) 0.78
Adipose tissue dysfunction and its effects on tumor metabolism. Horm Mol Biol Clin Investig (2015) 0.77
A Balanced Tissue Composition Reveals New Metabolic and Gene Expression Markers in Prostate Cancer. PLoS One (2016) 0.77
[Immunohistochemical algorithms in prostate diagnostics: what's new?]. Pathologe (2009) 0.77
Association and regulation of protein factors of field effect in prostate tissues. Int J Oncol (2016) 0.75
Altered Mitochondrial Signalling and Metabolism in Cancer. Front Oncol (2017) 0.75
Fatty acid synthase regulates estrogen receptor-α signaling in breast cancer cells. Oncogenesis (2017) 0.75
Overexpression of the androgen receptor in human hepatoma cells and its effect on fatty acid metabolism. Oncol Lett (2017) 0.75
ACSL3 promotes intratumoral steroidogenesis in prostate cancer cells. Cancer Sci (2017) 0.75
CEACAM1 as a multi-purpose target for cancer immunotherapy. Oncoimmunology (2017) 0.75
Interaction between von Hippel-Lindau Protein and Fatty Acid Synthase Modulates Hypoxia Target Gene Expression. Sci Rep (2017) 0.75
Loss of ABHD5 promotes the aggressiveness of prostate cancer cells. Sci Rep (2017) 0.75
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med (2004) 13.57
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut (2008) 6.26
CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature (2008) 6.24
Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature (2002) 6.10
Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature (2008) 6.04
Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn (2005) 6.00
Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn (2006) 4.68
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature (2011) 4.57
Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal (2010) 4.15
CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn (2006) 3.98
EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science (2012) 3.74
Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn (2007) 3.56
The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature (2011) 3.37
Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest (2002) 3.36
Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci U S A (2003) 3.34
An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med (2010) 3.09
Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol (2009) 2.94
Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol (2006) 2.80
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov (2014) 2.79
Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol (2008) 2.75
Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res (2008) 2.58
Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst (2009) 2.53
Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer (2008) 2.53
A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell (2008) 2.48
Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell (2007) 2.43
Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. Cancer Res (2002) 2.33
Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res (2004) 2.32
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet (2013) 2.29
The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell (2004) 2.27
MYC regulation of a "poor-prognosis" metastatic cancer cell state. Proc Natl Acad Sci U S A (2010) 2.21
The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev (2012) 2.13
Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res (2009) 2.13
Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res (2005) 2.13
Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer. J Urol (2005) 2.01
Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol (2010) 2.00
Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. Cancer Res (2003) 1.99
Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol (2008) 1.88
ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev (2013) 1.87
Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Neoplasia (2006) 1.84
Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res (2003) 1.83
Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res (2005) 1.82
p63 regulates commitment to the prostate cell lineage. Proc Natl Acad Sci U S A (2005) 1.80
Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma. J Cell Mol Med (2009) 1.79
Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase. Proc Natl Acad Sci U S A (2005) 1.73
Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer. Cancer Res (2004) 1.72
Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma. J Am Soc Nephrol (2005) 1.71
Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line. Cancer Res (2002) 1.69
The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res (2006) 1.69
Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res (2005) 1.68
Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res (2013) 1.66
A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol (2011) 1.64
c-Myc phosphorylation is required for cellular response to oxidative stress. Mol Cell (2006) 1.64
Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry. Clin Cancer Res (2009) 1.61
Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice. J Biol Chem (2005) 1.59
CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch (2007) 1.57
Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is correlated with microsatellite instability and CIMP. Mod Pathol (2006) 1.57
The EZH2 polycomb transcriptional repressor--a marker or mover of metastatic prostate cancer? Cancer Cell (2002) 1.56
The ubiquitin-specific protease USP2a enhances tumor progression by targeting cyclin A1 in bladder cancer. Cell Cycle (2012) 1.56
Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc Natl Acad Sci U S A (2010) 1.55
Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer. Breast Cancer Res Treat (2003) 1.54
The isopeptidase USP2a protects human prostate cancer from apoptosis. Cancer Res (2006) 1.52
Telomere length influences cancer cell differentiation in vivo. Mol Cell Biol (2013) 1.52
Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. J Clin Invest (2009) 1.51
Differential requirement of mTOR in postmitotic tissues and tumorigenesis. Sci Signal (2009) 1.47
The fat side of prostate cancer. Biochim Biophys Acta (2013) 1.46
The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod Pathol (2004) 1.44
Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res (2004) 1.42
Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet (2010) 1.40
mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol (2011) 1.40
Differential p53-independent outcomes of p19(Arf) loss in oncogenesis. Sci Signal (2009) 1.39
Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol (2011) 1.39
ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. J Clin Invest (2013) 1.38
Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. J Clin Oncol (2010) 1.37
Development of an integrated prostate cancer research information system. Clin Genitourin Cancer (2006) 1.36
Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients. Mod Pathol (2008) 1.35
Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein. Mol Cancer Res (2003) 1.34
Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. Proc Natl Acad Sci U S A (2012) 1.34
Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors. Clin Cancer Res (2007) 1.34
Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer. Mol Cancer Res (2006) 1.33
Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol (2010) 1.30
Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer. Lab Invest (2008) 1.30
Identification of prostate cancer modifier pathways using parental strain expression mapping. Proc Natl Acad Sci U S A (2007) 1.29
Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma. Am J Surg Pathol (2006) 1.29
Obligate roles for p16(Ink4a) and p19(Arf)-p53 in the suppression of murine pancreatic neoplasia. Mol Cell Biol (2002) 1.28
Metabolic alterations and targeted therapies in prostate cancer. J Pathol (2010) 1.28
Downregulation of miR-101 in gastric cancer correlates with cyclooxygenase-2 overexpression and tumor growth. FEBS J (2012) 1.28
TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer. Hum Pathol (2007) 1.27
c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme. J Pathol (2009) 1.26
Fatty acid synthase inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model. Int J Cancer (2008) 1.25
Intermediate basal cells of the prostate: in vitro and in vivo characterization. Prostate (2003) 1.23
Do-it-yourself (DIY) pathology. Nat Biotechnol (2008) 1.23